BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Milder DA, Milder TY, Kam PCA. Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations. Anaesthesia 2018;73:1008-18. [DOI: 10.1111/anae.14251] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Lui DTW, Wu T, Au ICH, Liu X, Fung MMH, Lee CH, Fong CHY, Woo YC, Lang BHH, Tan KCB, Wong CKH. A Population-Based Study of SGLT2 Inhibitor-Associated Postoperative Diabetic Ketoacidosis in Patients with Type 2 Diabetes. Drug Saf 2022. [DOI: 10.1007/s40264-022-01247-3] [Reference Citation Analysis]
2 Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein H, Müller-Wieland D, Nauck MA, Wiesner T, Siegel E. Therapy of Type 2 Diabetes. Exp Clin Endocrinol Diabetes 2022. [PMID: 35839797 DOI: 10.1055/a-1624-3449] [Reference Citation Analysis]
3 Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein HH, Müller-wieland D, Nauck MA, Wiesner T, Siegel E. Therapie des Typ-2-Diabetes. Diabetologie 2022;18:623-656. [DOI: 10.1007/s11428-022-00921-5] [Reference Citation Analysis]
4 Salukhov VV, Galstyan GR, Ilyinskay TA. Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives. Diabetes mellitus 2022;25:275-287. [DOI: 10.14341/dm12855] [Reference Citation Analysis]
5 Kietaibl A, Fasching P, Glaser K, Petter-puchner AH. New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature. Front Surg 2022;9:828649. [DOI: 10.3389/fsurg.2022.828649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sohatee M, Holland J. Life-threatening complications for diabetic patients taking SGLT2 inhibitors when undergoing surgery: A poorly recognised problem? J Perioper Pract 2022;:17504589211024409. [PMID: 35291825 DOI: 10.1177/17504589211024409] [Reference Citation Analysis]
7 Singhal R, Hechanova LA. SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes. Curr Cardiol Rep 2022. [PMID: 35147891 DOI: 10.1007/s11886-022-01637-0] [Reference Citation Analysis]
8 Vadi S, Lad V, Kapoor D. Perioperative Implication of Sodium-glucose Cotransporter-2 Inhibitor in a Patient Following Major Surgery. Indian J Crit Care Med 2021;25:958-9. [PMID: 34733046 DOI: 10.5005/jp-journals-10071-23929] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Buck S, Russo SG. [Perioperative Ketoacidosis under SGLT2-Inhibitors]. Anasthesiol Intensivmed Notfallmed Schmerzther 2021;56:704-8. [PMID: 34704247 DOI: 10.1055/a-1493-0280] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rupprecht B, Stöckl A. [Perioperative Management of Long-term Antidiabetic Therapy in Patients with Diabetes Mellitus]. Anasthesiol Intensivmed Notfallmed Schmerzther 2021;56:679-90. [PMID: 34704245 DOI: 10.1055/a-1226-4733] [Reference Citation Analysis]
11 Yeoh HL, Lee M, Pan WJ, Ong HY. Case of sodium-glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis. BMJ Case Rep 2021;14:e235953. [PMID: 34404640 DOI: 10.1136/bcr-2020-235953] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Fookeerah P, Law H, Ali F, Chatten K, Kim C, Cheung NW. An audit of the effect of SGLT2 inhibitor cessation in a pre-admission clinic before and after Australian Diabetes Society guidelines. Intern Med J 2021;51:980-3. [PMID: 34155765 DOI: 10.1111/imj.15366] [Reference Citation Analysis]
13 Wohlrab P, Kainz M, Schiferer A, Zapletal B, Tschernko E. Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus: A Case Report. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00633-9. [PMID: 34465512 DOI: 10.1053/j.jvca.2021.07.048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Rauch-Kröhnert U, Landmesser U. [Gliflozins-in future cardioprotective drugs?]. Internist (Berl) 2021;62:786-95. [PMID: 34164700 DOI: 10.1007/s00108-021-01083-0] [Reference Citation Analysis]
15 Chandrashekar M, Philip S, Nesbitt A, Joshi A, Perera M. Sodium glucose-linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications. Int J Urol 2021. [PMID: 34155680 DOI: 10.1111/iju.14624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein HH, Müller-wieland D, Nauck MA, Reuter H, Siegel E. Therapie des Typ-2-Diabetes. Diabetologe 2021;17:422-447. [DOI: 10.1007/s11428-021-00765-5] [Reference Citation Analysis]
17 Klein AA, Meek T, Allcock E, Cook TM, Mincher N, Morris C, Nimmo AF, Pandit JJ, Pawa A, Rodney G, Sheraton T, Young P. Recommendations for standards of monitoring during anaesthesia and recovery 2021: Guideline from the Association of Anaesthetists. Anaesthesia 2021;76:1212-23. [PMID: 34013531 DOI: 10.1111/anae.15501] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 50.0] [Reference Citation Analysis]
18 Smith A, Holtrop J, Sadoun M. Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy. Cureus 2021;13:e14297. [PMID: 33968511 DOI: 10.7759/cureus.14297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Goto S, Ishikawa JY, Idei M, Iwabuchi M, Namekawa M, Nomura T. Life-Threatening Complications Related to Delayed Diagnosis of Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Report of 2 Cases. Am J Case Rep 2021;22:e929773. [PMID: 33723205 DOI: 10.12659/AJCR.929773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pontes JPJ, de Melo CS, Arantes FBB, de Souza Ramos JTG, Módolo NSP, Navarro E Lima LH. Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery. J Clin Anesth 2021;71:110201. [PMID: 33647525 DOI: 10.1016/j.jclinane.2021.110201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
21 Koyro TF, Thottakara T, Huber TB, Harendza S. [Metabolic acidosis of surprising origin in a 61-year-old female patient]. Internist (Berl) 2021;62:549-54. [PMID: 33326044 DOI: 10.1007/s00108-020-00922-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Bamgboye AO, Oni IO, Collier A. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol 2021;77:651-7. [PMID: 33244632 DOI: 10.1007/s00228-020-03051-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
23 Williams DM, Nawaz A, Evans M. Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials. Diabetes Ther 2021;12:55-70. [PMID: 33185854 DOI: 10.1007/s13300-020-00951-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
24 Landgraf R, Aberle J, Birkenfeld AL, Gallwitz B, Kellerer M, Klein HH, Müller-wieland D, Nauck MA, Reuter H, Siegel E. Therapie des Typ-2-Diabetes. Diabetologie und Stoffwechsel 2020;15:S65-92. [DOI: 10.1055/a-1193-3793] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
25 O'Neill RS, Tyack L, Freeman M, Hussein HS. Euglycemic Ketoacidosis in a Patient with Metastatic Non-Small-Cell Lung Adenocarcinoma and Concomitant Pulmonary Embolism. Case Rep Endocrinol 2020;2020:8882299. [PMID: 32832169 DOI: 10.1155/2020/8882299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Wang KM, Isom RT. SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report. Kidney Med 2020;2:218-21. [PMID: 32734242 DOI: 10.1016/j.xkme.2019.12.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
27 Koufakis T, Mustafa OG, Ajjan RA, Garcia-Moll X, Zebekakis P, Dimitriadis G, Kotsa K. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking? J Clin Pharm Ther 2020;45:883-91. [PMID: 31905245 DOI: 10.1111/jcpt.13107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
28 Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. British Journal of Anaesthesia 2019;123:27-36. [DOI: 10.1016/j.bja.2019.03.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 18.3] [Reference Citation Analysis]
29 Nathanson MH, Dhatariya K. Correction. Anaesthesia 2019;74:810-810. [DOI: 10.1111/anae.14663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Charlesworth M, Feddy L, Wisely N. Sodium‐glucose co‐transporter type‐2 inhibitors: is the message getting through? Anaesthesia 2019;74:679-679. [DOI: 10.1111/anae.14619] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf 2019;18:295-311. [PMID: 30933547 DOI: 10.1080/14740338.2019.1602116] [Cited by in Crossref: 82] [Cited by in F6Publishing: 66] [Article Influence: 27.3] [Reference Citation Analysis]
32 Libianto R, Ekinci EI. New Agents for the Treatment of Type 2 Diabetes. Critical Care Clinics 2019;35:315-28. [DOI: 10.1016/j.ccc.2018.11.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
33 Poulton T, Murray D; the National Emergency Laparotomy Audit (NELA) project team. Pre-optimisation of patients undergoing emergency laparotomy: a review of best practice. Anaesthesia 2019;74:100-7. [DOI: 10.1111/anae.14514] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
34 Pace DJ, Dukleska K, Phillips S, Gleason V, Yeo CJ. Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter 2 Inhibitor Use in Two Patients Undergoing Pancreatectomy. J Pancreat Cancer 2018;4:95-9. [PMID: 30631862 DOI: 10.1089/pancan.2018.0016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]